Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ) announced its third-quarter results for 2025. During the first three quarters, the company achieved operating revenue of RMB1.434 billion, marking a 3.57% year-on-year increase. Net profit attributable to shareholders of the listed company reached RMB223 million, surging 75.81% compared to the same period last year. After excluding non-recurring gains and losses, the net profit stood at RMB186 million, reflecting an 81.89% year-on-year growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments